Cargando…

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies

INTRODUCTION AND OBJECTIVE: Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due to serous retinopathy. METHODS: Four studies evaluating cobimetinib at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barteselli, Giulio, Goodman, Grant R., Patel, Yogesh, Caro, Ivor, Xue, Cloris, McCallum, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700562/ https://www.ncbi.nlm.nih.gov/pubmed/36310331 http://dx.doi.org/10.1007/s40264-022-01248-2

Ejemplares similares

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
por: de la Cruz-Merino, Luis, et al.
Publicado: (2017)

Progressive nodular histiocytosis with dramatic response to cobimetinib
por: Berce, Philip C., et al.
Publicado: (2022)

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
por: Sherman, E., et al.
Publicado: (2023)

Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature
por: Di Nicola, Maura, et al.
Publicado: (2015)

Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib
por: Giuffrè, Chiara, et al.
Publicado: (2020)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

Steroid-induced central serous retinopathy
por: Shah, Samidh P., et al.
Publicado: (2011)

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells
por: Singh, Anjali, et al.
Publicado: (2015)

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
por: Iafolla, Marco AJ, et al.
Publicado: (2019)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient
por: King, Amber C., et al.
Publicado: (2019)

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
por: Lulli, Daniela, et al.
Publicado: (2017)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
por: Cheeti, Sravanthi, et al.
Publicado: (2020)

Enfermedad de Erdheim-Chester: una rara histiocitosis con excelente respuesta a cobimetinib
por: Sosa, Gabriela Alejandra, et al.
Publicado: (2021)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

Vemurafenib- and Cobimetinib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Metastatic Melanoma
por: Al-Saedy, Miriam, et al.
Publicado: (2023)

Clinical applications of choroidal imaging technologies
por: Chhablani, Jay, et al.
Publicado: (2015)

Photoreceptor disruption and vision loss associated with central serous retinopathy
por: Sun, Lynn W., et al.
Publicado: (2017)

Purtscher-like retinopathy with serous macular detachment in pre-eclampsia
por: Ozdamar Erol, Yasemin, et al.
Publicado: (2018)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
por: Alekseev, Oleg, et al.
Publicado: (2021)

Ayurvedic management central serous retinopathy - A case report
por: Shanti, K., et al.
Publicado: (2023)

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib
por: Medina, Theresa M, et al.
Publicado: (2016)

A novel side effect of mitogen-activated protein kinase inhibitor cobimetinib: Acute corneal decompensation
por: Asfuroğlu, Mahmut, et al.
Publicado: (2019)

Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
por: Riancho, José A., et al.
Publicado: (2023)

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
por: Lieu, Christopher H., et al.
Publicado: (2017)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Multiple Drug Regimen-Refractory Rosai–Dorfman–Destombes Disease Mimicking Relapsing Polychondritis Successfully Treated with Cobimetinib
por: López-Aldabe, Kima, et al.
Publicado: (2022)

Central serous retinopathy and hand–foot–mouth disease: coincidence or causation?
por: Taylor, Selina, et al.
Publicado: (2018)

A Masquerade Case: Choroidal Hemangioma Misdiagnosed As Central Serous Retinopathy
por: Lai, Leo, et al.
Publicado: (2023)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
por: Lewis, Karl D., et al.
Publicado: (2019)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
por: Kawaguchi, Kei, et al.
Publicado: (2017)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening
por: Yang, Shilun, et al.
Publicado: (2022)

Neoplastic leptomeningeal disease masquerading as central serous retinopathy. A case report
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rbuomg6pcstmsu4895m50ge84q